Kornimate/medical-research-clean huggingface dataset:
home-based computer gaming in vestibular rehabilitation

Conditions: Peripheral Vestibular Disorders; Vestibular Syndromes &/or Disorders (Labyrinthine); Vestibular Neuronitis

Summary: it is hypothesized that a home-based computer gaming rehabilitation program will improve gaze control and balance impairments in those with peripheral vestibular disorders (pvd). ten people with peripheral vestibular disorders were started on a treatment program that consisted of playing computer games and while performing various balance exercises. on a weekly basis, each participant was contacted by email or telephone and asked to submit their computer gaming data to a trained vestibular physical therapist. following review of this data, the physical therapist would contact the participant and progress their computer gaming program appropriately. at the completion of twelve weeks of home treatment, the participants returned for re-assessment and it was determined that the computer gaming program was an effective treatment for those with pvd. it was also determined that a monitored telerehabilitation program was an efficient and effective delivery method for this treatment.

a pre to post intervention case series study was carried out on ten participants diagnosed with peripheral vestibular disorders (pvd). inclusion criteria consisted of: a) 20 to 70 year old, b) confirmed diagnosis of pvd on neuro-opthalmic, neuro-orthoptic, electronystagmography and caloric testing; and use of a home computer. exclusion criteria consisted of those with migraine, central nervous system disorders (for example cerebral vascular accident or multiple sclerosis), recent fractures of the spine or lower extremities, inability to stand for 20 minutes continuously, or presence of dementia. it was hypothesized that a home-based computer gaming treatment delivered in a monitored telerehabilitation platform would be an effective treatment for those with pvd in that increased gaze stability and improved balance would be observed post-treatment. it was also hypothesized that decreased dizziness would be reported post-treatment. after initial assessment (pre-treatment), three in-clinic sessions were given to each participant to develop their specific home treatment computer program and ensure ability to use the program effectively. they were then started on their home program and monitored by a trained vestibular physical therapist for a 12-week telerehabilitation program. after the completion of the 12-weeks, the participants returned for a post-treatment assessment.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of peripheral vestibular disorder (confirmed on electronystagmography, bithermal caloric testing, neuro-ophthalmic, neuro-orthoptic examination) * access to a home computer exclusion criteria: * central nervous system disorders * vestibular migraine * benign paroxysmal positional vertigo (bppv) * recent fractures of the spine or lower extremities * inability to tolerate standing for 20 minutes

Keywords: dizziness vertigo unsteadiness unbalance falls
comparison of postoperative pain between patients received primary and repeated caesarean section

Conditions: Caesarean Section

Summary: to everyone knows, more and more patients received repeated caesarean section in china. however, at present it is not known what is it like about their postoperative pain intensity, and is it different from those patients who received primary caesarean section. thus through postoperative follow-up, the current study aimed to investigate and compare the postoperative pain between patients received primary and repeated caesarean section.

according to whether or not to receive repeated caesarean patients were grouped into group p or group r. for all maternal,standardized epidural anesthesia and caesarean section were performed. then the pain vas scores and ramsay scores at 4h, 8h, 12h, 24h and 48h after the surgery were recorded. and sleep quality at 1 day and 2 day after the surgery were recorded. in addition, pain situation at 1 week and 4 weeks after the surgery was followed up.

Eligibility criteria:
inclusion criteria: * single birth * full-term pregnancy * in accordance with cesarean section indications * transverse incision of lower uterine segment exclusion criteria: * history of dementia, psychiatric illness or any diseases of central nervous system * accompanying liver or kidney function deficiency * alcoholism and drug dependence * patients previously included in this study or currently included in the other clinical study * patients who have second surgery during the study period * difficult to follow up or patients with poor compliance * history of chronic pain
an open-label trial of memantine in the treatment of binge eating disorder

Conditions: Binge Eating Disorder

Summary: we hypothesize that memantine may be a safe and effective treatment for moderate to severe binge eating disorder associated with obesity. during this 12-week, open-label, outpatient study, male and female subjects between the ages of 18 and 65 years who have moderate to severe binge eating disorder and are obese will be treated with open-label memantine. following this 12-week treatment phase, subjects may be eligible to continue into an extension phase which will last an additional 12 weeks. during the extension phase subjects will continue open-label memantine treatment.

binge eating disorder is a newly recognized disorder characterized by recurrent episodes of binge eating without extreme behaviors to lose weight characteristic of bulimia nervosa or anorexia nervosa and it is associated with overweight and obesity in both clinical and community populations. preliminary clinical data from a recent, small, 5-week, open-label therapeutic trial in obese patients with binge eating disorder in germany found memantine to be effective in weight reduction and reduction of binge episodes. we plan to study 15 male and female subjects between the ages of 18 and 65 years who have binge eating disorder (with 3 or more binge days per week in the 2 weeks prior to baseline) and have a body mass index (bmi) between 30 and 50 kg/m2. during the 12-week treatment phase subjects will receive open-label memantine titrated up to 20mg/day, or the subjects maximum tolerated dose. upon completion of the treatment phase, subjects will either taper their study medication and return for a final post-taper visit or continue on their current dose of study medication in the 12-week extension phase.

Eligibility criteria:
inclusion criteria: * subjects may be male or female, 18-65 years old * diagnosis of binge eating disorder * subjects must have 3 or more binge days per week for the two weeks prior to the start of the study * subjects must have a bmi between 30 and 50 kg/m2 exclusion criteria: * current or lifetime history of schizophrenia, other psychotic disorder, or bipolar disorder * subjects with a history of a personality disorder * subjects with clinically significant depression * subjects with substance use of dependence * subjects who are pregnant or lactating * subjects with a serious medical condition

Keywords: binge eating obesity eating disorder
pharmacokinetics of acetaminophen in morbidly obese patients

Conditions: Morbid Obesity

Summary: this study will investigate the pharmacokinetics of acetaminophen in morbidly obese patients versus normal weight patients. specifically the different metabolic pathways of acetaminophen in morbidly obese adults will be investigated; glucuronidation, sulphation and cyp2e1 (cytochrome p450 2e1) oxidation


Eligibility criteria:
inclusion criteria for morbidly obese patients: * bmi \> 40 kg/m2 undergoing bariatric surgery. * patients between 18 - 60 years old * asa physical classification of ii or iii * all racial and ethnic groups will be included inclusion criteria for control group: * bmi between 18 and 25 kg/m2 undergoing general surgery * patients between 18 - 60 years old * asa (american society of anesthesiology) physical classification of i, ii or iii * all racial and ethnic groups will be included exclusion criteria for all study arms: * renal insufficiency * liver disease * patients with gilbert-meulengracht syndrome * chronic alcohol intake or use of alcohol within last 72 hours * pregnancy or breastfeeding * patients who are treated with drugs know to affect cyp2e1 and ugt (udp glucuronosyltransferase) * diabetes mellitus type ii patients * smoking * acetaminophen intake before the study (24 hours before study)
clinical outcomes of patients with clostridium difficile associated disease attributable to diverse tcdc genotypes

Conditions: Clostridium Infections

Summary: the purpose of the study is to establish the clinical disease outcomes and features of cdad associated with variant tcdc genotypes. two hypotheses are to be tested in this study: 1. severe cdad and tcdc truncation: severe cdad (defined by death and/or colectomy or secondary endpoints) is associated with severe truncations (\> 6 amino acid residues) in tcdc, a negative regulator of toxin a/b production. 2. disease in low risk populations (patients never exposed to health care facilities and/or patients who never received antibiotics) of any severity is attributable to strains of c. difficile with severe tcdc truncation.

the following information will be collected: age, sex, occupation, hospital location at the time of positive culture (er, medical ward, icu etc), prior hospitalization, receipt of outpatient dialysis, home care or other regular medical care (eg, outpatient chemotherapy), date of specimen collection, presence of invasive devices, receipt of antibiotics, including their type and whether they were adequate for the resistance profile of the organism, prior positive microbiologic cultures, time and location of positive cultures, underlying diseases and severity of illness, presence of urinary or intravascular devices, recent immunomodulative therapies or radiation therapy, physical exam findings, laboratory and radiographical data, antimicrobial usage within 6 months of onset of the infection, microbiological data and resistance patterns, choice of antibiotics once organism identified, bacteriological outcomes, laboratory results, demographic information, medications, clinical outcome,gender, height, weight, ethnicity, past medical history and outcomes. we will collect information retrospectively.

Eligibility criteria:
inclusion criteria: * all patients who have confirmed cdad, confirmed by testing at upmc's clinical microbiology lab in march 1, 2001- december 31, 2005 for c. difficile by stool toxin test with subsequent positive culture for the organism from inpatients/outpatients at upmc presbyterian-montefiore, from wpic inpatient units, from er visits at the presbyterian university hospital emergency department, and from clinics closely affiliated with upmc presbyterian (medical and surgical clinics in falk clinic, the 9 south montefiore internal medicine clinic, the geriatrics clinic in montefiore, and the digestive disorders center (gi clinic on 3rd floor of puh).

Keywords: c diff antibiotics
cwt versus at on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.

Conditions: Ischemic Cardiomyopathy

Summary: to compare between the effect of circuit weight and aerobic training on selected cardiovascular indices and functional capacity in patients with ischemic cardiomyopathy.

ischemic cardiomyopathy (icm) is a term that refers to the heart's decreased ability to pump blood properly due to myocardial damage brought upon by ischemia. ischemic cardiomyopathy has a spectrum of clinical changes which eventually leads to congestive heart failure (chf). initially, there is a reversible loss of cardiac contractile function because of decreased oxygen supply to the heart muscle; however, when there is ischemia for a prolonged period, there is irreversible cardiac muscle damage resulting in cardiac remodeling. remodeling is primarily achieved by myocardial fibrosis which results in decreased cardiac function, arrhythmia, and possible cardiac conduction system impairment. in ischemic cardiomyopathy, there is a significant impairment of the left ventricular systolic function, with a left ventricular ejection fraction (lvef) less than 40% (bhandari et al., 2021).

Eligibility criteria:
inclusion criteria: * sixty male patients with ischemic cardiomyopathy as a result of a recent acute myocardial infarction event (≤2 months) with 40%\<lvef\<50%. * they are functionally classified as class ii according to new york heart association (nyha). * their age will be ranged from 45 to 55 years old. * their bmi will be ranged from 25 to 29.9 kg/m². * they will have good mentality. exclusion criteria: * recurrent coronary heart disease. * severe valvular diseases. * underlying pulmonary disease (aspiration pneumonia, chronic obstructive pulmonary disease, pneumothorax, etc.). * inability to ambulate owing to physical problems (paresis induced by cerebral stroke, spinal cord injury, amputation, severe pain, dyspnea, etc.). * muskloskletal problems (e.g. severe osteoarthritis or ankylosing spondylitis). * impaired cognitive function (vascular dementia, alzheimer's dementia, other psychological disease, etc.)
effect of mannitol on optic nerve sheath diameter in patients undergoing robotic prostatectomy

Conditions: Prostate Cancer

Summary: we aim to evaluate the change in optic nerve sheath diameters as a surrogate of intracranial pressure before and after mannitol administration in patients who undergo robot assisted laparoscopic radical prostatectomy with pneumoperitoneum and trendelenburg position.

mannitol has been frequently used for renal protection during surgery. optic nerve sheath diameter is used to evaluate intracranial pressure noninvasively. robot-assisted laparoscopic radical prostatectomy can induce an increase in optic nerve sheath diameter due to trendelenburg position and carbon dioxide insufflation. we therefore aim to evaluate the change in optic nerve sheath diameters before and after mannitol administration in patients who undergo robot assisted laparoscopic radical prostatectomy.

Eligibility criteria:
inclusion criteria: * prostate cancer patients undergoing robot assisted laparoscopic radical prostatectomy. * 20 year old or above, 79 year old or below. * agreed to participate this study. exclusion criteria: * history of cerebrovascular accident. * history of congestive heart failure. * history of pulmonary edema. * history of anaphylaxis to mannitol. * conversion to open prostatectomy. * combined with other operation. * inability to measure optic nerve sheath diameter.
intensive statin treatment in acute ischemic stroke patients with intracranial atherosclerosis

Conditions: Stroke; Intracranial Atherosclerosis

Summary: purpose: intracranial atherosclerosis is a common condition in korean population consisting over 25% of ischemic stroke etiology. american stroke association and korean stroke society recommend antiplatelet and statin for the treatment of intracranial atherosclerosis. besides lowering blood cholesterol levels statin also stabilize atherosclerotic plaque and eventually lower the risk of ischemic stroke. however, little evidence resides on the effect of statin treatment on intracranial atherosclerosis. recent advance in high-tesla magnetic resonance imaging enables direct imaging of intracranial atherosclerotic plaque and further assessment of treatment efficacy of statin in stabilization of intracranial atherosclerotic plaque became possible.


Eligibility criteria:
inclusion criteria: * acute ischemic stroke patients within 7 days of symptom onset * symptomatic intracranial artery stenosis (above 30%) at proximal portion of middle cerebral artery (mca), basilar artery, or intracranial portion of intracranial artery (ica). * not receiving statins (hma-coa reductase) * willing and able to comply with scheduled visits, lifestyle guidelines, treatment plan, laboratory tests, and other study procedures. exclusion criteria: * extracranial artery (carotid artery bifurcation, proximal vertebral artery) stenosis above 50% * stroke attributable to cardioembolic origin (atrial fibrillation, valvular heart disease, aortic arch atherosclerosis) * severe hepatic or renal dysfunction * pregnant females as determined by positive urine hcg test or lactating females * subjects considered unwilling or unable to comply with the imaging procedures and study visit schedule
pediatric action3 (identify, treat, control): effectiveness of adding montelukast in pediatric subjects with uncontrolled asthma (0476-385)

Conditions: Asthma

Summary: a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids


Eligibility criteria:
inclusion criteria: * patient is diagnosed with asthma for at least 6 months * patient's peak expiratory flow (pef) is 80% of predicted value (appendix 10) * patient is currently untreated, or patient is a user of short-acting 2-agonist on an as-needed basis, or patient is a user of ics at any dosage * physician and/or patient are dissatisfied with current controller therapy, or patient is reluctant to take ics therapy, or patient is insufficiently controlled due to non-adherence with current therapy through the preceding 6 weeks exclusion criteria: * as per canadian guidelines, patient is on a laba alone (formoterol (oxeze), salmeterol (serevent)) or a combination product (advair or symbicort) * patient is well controlled, adherent and satisfied with current controller therapy
observational study of patients who underwent diagnostic investigation (prostate biopsy) and/or radical prostatectomy surgery.

Conditions: Prostate Cancer

Summary: this is a single-center, observational, prospective and retrospective study on quality of life and disease status of patients who underwent prostate biopsy and/or radical prostatectomy.

a database was created with the intention of collecting data related to patients who underwent prostate biopsy and/or radical prostatectomy. only anamnesis and biopsy procedure data are collected for patients underwent prostate biopsy. anamnesis, surgery, histological report and hospitalization data are collected for patients who underwent radical prostatectomy. each patient will be followed for 50 years from the date of radical prostatectomy surgery. each patient will receive a questionnaire before radical prostatectomy. a follow up questionnaire will be collected after surgery relating to quality of life. the data for each patient will then be transferred to the database itself. the data collected will be handled following the most strict gcps and privacy norms.

Eligibility criteria:
inclusion criteria: * patients with a suspicious prostate disease who underwent prostate biopsy and/or radical prostatectomy; * adult patients \> 18 years * ability to read and sign the informed consent exclusion criteria: * patients \< 18 years * mental or physical disability that may prevent the patient from satisfying the requirements of the protocol * inability to read and sign the informed consent
quantification of the differences in the diagnostic relationships between centric occlusion versus maximum intercuspation in adult orthodontic patients : a cross-sectional study

Conditions: Centric Relation Registration

Summary: the aim of the study is to quantify the differences in the diagnostic relationships between centric occlusion versus maximum intercuspation in adult orthodontic patients with cetric relation recoded using both conventional method utilizing semi-adjustable articulator and face bow record in addition to digital method proposed by radu et al for finding and recording cr using a dental intraoral scanner with a leaf gauge

study design cross-sectional study pico components p: adult orthodontic patient i: centric occlusion c: maximum intercuspation o: -orthodontic relations: molar relation canine relation incisor relation overjet overbite midline discrepancy

Eligibility criteria:
inclusion criteria: orthodontic patient having full permanent dentition exclusion criteria: * patients who had undergone previous orthodontic treatment, and syndromic patients, retained primary teeth , teeth heavily restored
evaluation of a new ultrasound system for the non-invasive assessment of liver steatosis in masld/mash patients

Conditions: Metabolic Syndrome X; Fatty Liver; MASH - Metabolic Dysfunction-Associated Steatohepatitis; MASLD

Summary: the objective of the study is to evaluate a new ultraportable ultrasound device, hepatoscope, for the non-invasive assessment of hepatic steatosis in patients presenting with steatopathy from metabolic origin, by comparing its measurements with current diagnostic modalities, such as mri pdff.

the objective of the study is to evaluate a new ultraportable ultrasound device, hepatoscope, for the non-invasive assessment of hepatic steatosis in patients presenting with steatopathy from metabolic origin, by comparing its measurements with current diagnostic modalities, such as mri pdff. the primary objective is to compare ultrasound parameters measurements of ultrasound attenuation, backscattering coefficient and sound speed to the hepatic fat fraction as measured with mri-pdff. the secondary objectives also include the comparison of measurements of liver stiffness as an indicator of liver fibrosis risk in patients at risk of having mash. exploratory objectives have been determined to allow the comparison of said measured parameters to the outcome of histopathological analysis in a subset patient population who would benefit from a liver biopsy.

Eligibility criteria:
inclusion criteria: * adult patient below 80 yo * patients with masld/mash recruited in interventional trials requiring mri pdff +/- mre per interventional protocol, or * patients with masld/mash recruited in prospective cohorts requiring mri pdff +/- mre per interventional protocol, or * patients referred to mri-pdff or mre. * patients who consented in written to participate in the study * patients with ongoing social security coverage exclusion criteria: * patient in their minority (less than 18 yo) or older than 80 yo, * patient with active implants, * patient presenting with a wound where the hepatoscope exman shall be performed (abdominal right upper quadrant) * patient with a history of decompensated cirrhosis, * patient with a history of hepatocellular carcinoma, * adult patient under tutorship, or unable to express informed consent, * pregnant or breast-feeding * person deprived from their liberty * patient hospitalized without providing consent or in case of an emergency * patient presenting with another know liver disease

Keywords: liver fibrosis steatosis elastography ultrasound attenuation backscattering coefficient sound speed mri pdff
events before death

Conditions: End Stage Renal Disease

Summary: previous studies of the patients treated in rri clinics suggest that hemodialysis patients undergo a certain consistent predictable pattern at the initiation of dialysis and before death. this pattern can be described as a group of patterns of patients' biological markers over a few months after starting dialysis and several months prior to death. additional patterns can be observed that occur with changes in seasons or time of day. the aim of this study is to compare these patterns in patients treated in fmc-asia, fmc-europe, fmc-south america, and rri-us populations. noting that patterns in patient parameters are similar across continents, climates, and geographic variations only further accentuates the importance in the models that can predict patients' survival and provide an opportunity for timely intervention.


Eligibility criteria:
inclusion criteria: * hemodialysis vintage 2+ months